WO2006077675A1 - 移植臓器の線維化抑制剤 - Google Patents
移植臓器の線維化抑制剤 Download PDFInfo
- Publication number
- WO2006077675A1 WO2006077675A1 PCT/JP2005/016653 JP2005016653W WO2006077675A1 WO 2006077675 A1 WO2006077675 A1 WO 2006077675A1 JP 2005016653 W JP2005016653 W JP 2005016653W WO 2006077675 A1 WO2006077675 A1 WO 2006077675A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- dna
- seq
- amino acid
- hgf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a drug containing a hepatocyte growth factor (hereinafter abbreviated as HGF) and suppressing fibrosis of a transplanted organ following long-term administration of an immunosuppressive agent.
- HGF hepatocyte growth factor
- the present invention also relates to an immunotolerant that includes a 5-amino acid-deficient HGF among HGFs and can acquire immune tolerance in organ transplant patients.
- Organ transplantation has become established as a medical treatment when there is no treatment other than replacing an organ.
- organ transplantation due to the increase in the number of engrafted organ transplants and the follow-up survey of patients after organ transplantation, it has become a problem that the transplanted organs gradually become fibrotic after many years after organ transplantation.
- immunosuppressive agents are used to suppress rejection of grafts or transplanted tissues. Except for autotransplantation, immunosuppressants must be taken for a lifetime, and fibrosis is observed in transplanted organs if the immunosuppressant is taken continuously.
- the causal relationship between the immunosuppressive agent and the fibrosis of the transplanted organ is not clear, there is no known means for suppressing the fibrosis of the transplanted organ under the administration of the immunosuppressant.
- immunosuppressive agents have been essential for the establishment of grafts or transplanted tissues, and have to be taken for a lifetime.
- cyclosporine and FK5 06 tacrolimus
- FK5 06 tacrolimus
- cyclosporine, etc. which is widely used for organ transplantation, has a low incidence of bone marrow suppression, leading to the development of serious infections associated with leukopenia This has the advantage of facilitating management after organ transplantation, and this effect has also made it possible to significantly improve the results of organ transplantation.
- side effects are also observed in cyclosporine, etc., such as nephrotoxicity, hepatotoxicity, neuropathy, hypertension, femoral head necrosis, cataract, diabetes, acute splenitis, cytomegalo Sites that are different from the transplant site such as rovirus infection and systemic side effects have been reported.
- HGF can reduce systemic side effects caused by such immunosuppressive agents (see Patent Document 1).
- HGF is a protein that Nakamura et al. Found as a factor for proliferating mature liver parenchymal cells in vitro from regenerated liver rat serum (see Non-Patent Document 1).
- Nakamura et al. also succeeded in isolating HGF from rat platelets (see Non-Patent Documents 2 and 3) and partially determined the amino acid sequence thereof.
- HGF suppresses fibrosis of the transplanted organ.
- Patent Document 1 Japanese Patent Laid-Open No. 08-89869
- Non-patent literature 1 Biochemical and biophysical research communations (Biochemical ana Biophysical Research Communications, 1984, 122, p. 1450-1459)
- Non-Patent Document 2 Proceedings ⁇ Ob ⁇ The ⁇ National ⁇ Academy ⁇ Ob ⁇ Science ⁇ Ob United State of America ( Proc . Natl. Acad. Sci), 1986, 83rd ⁇ , p. 6489
- Non-Patent Document 3 FEBS Letters, 1987, Vol. 22, p. 311
- Non-Patent Document 4 Nature, 1989, No. 342, p. 440-443 Disclosure of the Invention
- the present invention relates to a drug that suppresses progressive transplantation of a transplanted organ and induces organ failure in an organ transplant patient who has been administered an immunosuppressive agent for a long period of time.
- the present invention also relates to an agent for obtaining immune tolerance (taransplantation tolerance) that allows a patient to acquire immune tolerance against organ rejection when a donor organ that provides an organ is provided to a recipient recipient.
- immune tolerance taransplantation tolerance
- the present inventors have shown that the administration of HGF suppresses fibrosis of the transplanted organ of the animal transplanted with the organ, and that the organ transplanted animal administered with the 5-amino acid deficient HGF gives the transplant to the transplanted organ. It was found that immune tolerance was acquired. Based on these findings, the present inventors have further studied and completed the present invention.
- the present invention provides:
- HGF is a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2, or a peptide comprising substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or 2, acting as HGF
- the agent for inhibiting fibrosis of a transplanted organ according to the above (1) which is a peptide or a partial peptide thereof and acts as HGF,
- a fibrosis inhibitor for transplanted organs according to (3) above which is a DNA that encodes a peptide that hybridizes under stringent conditions with a DNA that acts as HGF,
- a peptide comprising the amino acid sequence represented by SEQ ID NO: 2 a peptide comprising substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2, and acting as HGF, or these
- An immunological tolerance acquiring agent comprising a partial peptide and a peptide acting as HGF, and
- DNA consisting of the base sequence represented by SEQ ID NO: 4 or DNA having the base sequence ability complementary to the DNA comprising the base sequence represented by SEQ ID NO: 4 under stringent conditions, and Contain DNA encoding a peptide that acts as HGF
- An immunological tolerance acquiring agent characterized by
- the present invention also provides:
- a method for suppressing fibrosis of a transplanted organ comprising administering HGF to a mammal transplanted into an organ to which an immunosuppressant is administered,
- HGF is a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2, or a peptide comprising an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 1 or 2, acting as HGF
- a method for suppressing fibrosis of a transplanted organ comprising administering a DNA encoding HGF to a mammal transplanted into an organ to which an immunosuppressant is administered,
- a method for obtaining immune tolerance comprising administering a peptide that acts as HGF or a partial peptide thereof that acts as HGF,
- a DNA having a nucleotide sequence represented by SEQ ID NO: 4 or a DNA comprising a nucleotide sequence complementary to the DNA represented by SEQ ID NO: 4 is stringent to a mammal to be transplanted into an organ.
- a method for obtaining immune tolerance characterized by administering DNA encoding a peptide that hybridizes under conditions and acts as HGF,
- the present invention also provides:
- HGF is a peptide comprising the amino acid sequence represented by SEQ ID NO: 1 or 2, or a peptide comprising an amino acid sequence substantially identical to the amino acid sequence represented by SEQ ID NO: 1 or 2, acting as HGF
- HGF is a peptide comprising the amino acid sequence represented by SEQ ID NO: 2, a peptide comprising substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1 or 2, and acting as HG F Or the use according to (20) above, which is a peptide that acts as HGF, which is a partial peptide thereof,
- fibrosis refers to a pathological condition in which an extracellular matrix such as collagen fibers (collagen) accumulates excessively in the transplanted organ, and as a result, the transplanted organ becomes hard.
- immune tolerance refers to the recipe of donor cells and tissues during organ transplantation. This refers to suppressing the destruction of the recipient's immune system so that it is not attacked by the recipient's immune system.
- the transplanted organ fibrosis inhibitor of the present invention suppresses fibrosis of the transplanted organ in an organ transplanted animal that has been administered an immunosuppressive agent for a long time, so that the transplanted organ gradually becomes fibrotic. , Can eventually prevent organ failure.
- the immunological tolerance acquiring agent of the present invention by administering the immunological tolerance acquiring agent of the present invention to an animal (patient) that is a force recipient immediately after transplanting a donor organ, immunity to the transplanted organ in the organ transplanted animal (patient) is achieved. Since tolerance can be obtained, rejection of the transplanted organ can be suppressed. Furthermore, an organ transplanted animal that has acquired immune tolerance against a donor by administration of the immunological tolerance acquiring agent of the present invention can induce a state without responsiveness to an immune response against a subsequent donor or donor organ. The dose of the suppressor can be reduced or administration of the immunosuppressant can be discontinued.
- a tissue other than the donor's transplanted organ (for example, a tissue involved in immunity described later) is transplanted, and the immune tolerance-acquiring agent of the present invention is administered to the recipient.
- Immunity tolerance can be acquired by the recipient.
- the recipient's tissue (for example, a tissue involved in immunity described below) is transplanted into the donor and the immune tolerance acquiring agent of the present invention is administered before organ transplantation to allow the donor to acquire immune tolerance against the recipient. You can also.
- rejection after organ transplantation The reaction can be suppressed or reduced. Suppression or reduction of the rejection allows the immunosuppressant to be stopped or the dose of the immunosuppressant to be reduced.
- mammals such as humans are of course included in the present invention.
- Figure 1 shows the pathology of the transplanted heart of a mouse surviving 60 days after heart transplantation (A) and the transplanted coronal shape. It is a figure which shows the ratio (B) of the fibrosis part area with respect to the total area of a section.
- FIG. 2 is a diagram showing that the white hair of a BALBZc mouse has settled on the black hair of a C3HZHe mouse.
- the HGF used in the present invention is a known substance, and any substance prepared by various methods can be used as long as it has been purified to the extent that it can be used as a medicine.
- a method for producing HGF for example, primary cultured cells or cell lines that produce HGF can be cultured, separated from the culture supernatant, and purified to obtain the HGF.
- the gene encoding HGF is incorporated into an appropriate vector by genetic engineering techniques, inserted into an appropriate host cell, and transformed, and the desired recombinant HGF is obtained from the culture supernatant of the transformant. You can also. (See, for example, JP-A-5-111382, Biochem. Biophys. Res. Commun. 1989, No. 163, p. 967).
- the above host cells are not particularly limited, and various host cells conventionally used in genetic engineering techniques, such as colon bacteria, yeast or animal cells, can be used.
- HGF thus obtained has substantially the same action as that of the natural HGF, one or more of its amino acid sequences [for example, several (for example, 1 to 8; hereinafter the same). ;)] Amino acid may be substituted, deleted or added, and the sugar chain may be similarly substituted, deleted or added.
- Examples of such HGF include the following 5-amino acid deficient HGF.
- “one or more amino acids are deleted, substituted or added” means that it occurs by a well-known technical method such as genetic engineering method, site-directed mutagenesis method, or the like It means that a sufficient number (1 to several) is deleted, substituted or added.
- HGF substituted, deleted, or added to a sugar chain is, for example, HGF that has been added to natural HGF! ⁇
- the amino acid sequence of the glycosylation site has been mutated, and some ⁇ has the amino acid sequence mutated so that the sugar chain is added to a site different from the natural glycosylation site.
- a protein having at least about 80% homology with the amino acid sequence of HGF preferably a protein having about 90% or more homology, more preferably about 95% or more homology.
- a protein that acts as HGF preferably a protein having about 90% or more homology, more preferably about 95% or more homology.
- “Homologous” in the above amino acid sequences means the degree of coincidence of amino acid residues constituting the respective sequences between the sequences by comparing the primary structures of the proteins.
- Examples of the HGF include an amino acid sequence represented by SEQ ID NO: 1 or 2.
- the HGF represented by SEQ ID NO: 2 is a 5-amino acid deficient HGF in which the 5th amino acid residue at positions 161 to 165 of the amino acid sequence represented by SEQ ID NO: 1 has been deleted.
- the proteins having the amino acid sequence represented by SEQ ID NO: 1 or 2 are both human-derived natural HGF, and have mitogenic activity, motogenic activity, etc. as HGF.
- the amino acid sequence represented by SEQ ID NO: 1 or 2 is at least about 80% or more, preferably about 90% or more More preferably, 1 to several amino acid residues are inserted or deleted from a peptide comprising an amino acid sequence having about 95% or more identity, such as the amino acid sequence represented by SEQ ID NO: 1 or 2.
- the amino acid to be inserted or substituted may be a non-natural amino acid other than the 20 amino acids encoded by the gene.
- the unnatural amino acid may be any compound as long as it has an amino group and a carboxyl group, and examples thereof include ⁇ -aminobutyric acid.
- peptides may be used alone or as a mixed peptide thereof.
- the C-terminus may be any of a carboxyl group (—COOH), a carboxylate (—COO—), an amide (—CONH), or an ester (COOR).
- R in the ester is, for example, a C alkyl group such as methyl, ethyl, ⁇ -propyl, isopyl pill, or ⁇ -butyl, such as cyclopentyl or cyclohexyl.
- C cycloalkyl groups such as syl, eg C aryl such as phenol, a naphthyl
- ferro-alkyl group such as benzyl, phenethyl, etc.
- C aralkyl groups such as ⁇ -naphthyl-C alkyl groups such as butylmethyl
- a bivalyloxymethyl group or the like generally used as an oral ester is used.
- the present invention HGF force used in the present invention has a carboxyl group (or carboxylate) other than the C-terminus, and those having a carboxyl group amidized or esterified are also included in the HGF in the present invention.
- the ester in this case for example, the C-terminal ester described above is used.
- the amino group of the N-terminal methionine residue is protected with a protecting group (for example, a C acyl group such as a formyl group, a C alkanoyl group such as acetyl), and the like.
- N-terminal side is living body
- Daltamyl group cleaved in the molecule forms pyroglutamic acid, and substituents on the side chain of amino acids in the molecule (for example, —OH, —SH, amino group, imidazole group, indole group, guazino group, etc. )
- substituents on the side chain of amino acids in the molecule for example, —OH, —SH, amino group, imidazole group, indole group, guazino group, etc.
- suitable protecting groups for example, C alkano such as formyl, acetyl, etc.
- a partial peptide of HGF used in the present invention (hereinafter sometimes abbreviated as partial peptide).
- the number of amino acids of the partial peptide is at least about 20 or more, preferably about 50 or more, more preferably about 100 or more amino acid sequences among the above-mentioned amino acid sequences of HGF. Etc. are preferred.
- the C-terminus may be any of a carboxyl group (—COOH), a carboxylate (—COO_), an amide (—CON H), or an ester (one COOR).
- partial peptides include
- the amino group of the N-terminal methionine residue is protected with a protecting group
- the N-terminal side is cleaved in vivo
- the Gin is pyroglutamic acid
- the amino acid in the molecule include those in which a substituent on the side chain is protected with an appropriate protecting group, or a complex peptide such as a so-called glycopeptide to which a sugar chain is bound.
- Examples of the salt of HGF or a partial peptide thereof used in the present invention include a physiologically acceptable salt with an acid or a base, and a physiologically acceptable acid addition salt is particularly preferable.
- Examples of such salts include salts with inorganic acids (eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid), or organic acids (eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid, And salts with succinic acid, tartaric acid, succinic acid, malic acid, succinic acid, benzoic acid, methanesulfonic acid, and benzenesulfonic acid).
- inorganic acids eg, hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid
- organic acids eg, acetic acid, formic acid, propionic acid, fumaric acid, maleic acid
- succinic acid tartaric acid
- succinic acid malic acid
- the partial peptide of HGF or a salt thereof used in the present invention can be produced according to a known peptide synthesis method or by cleaving HGF with an appropriate peptidase.
- a peptide synthesis method for example, either a solid phase synthesis method or a liquid phase synthesis method may be used. That is, when the partial peptide or amino acid capable of constituting HGF is condensed with the remaining part and the product has a protecting group, the desired peptide can be produced by removing the protecting group.
- Known condensation methods and protecting group removal include, for example, M.
- a partial peptide of HGF can be purified and isolated by a combination of usual purification methods such as solvent extraction 'distillation' force chromatography, liquid chromatography, recrystallization and the like.
- solvent extraction 'distillation' force chromatography liquid chromatography
- recrystallization recrystallization and the like.
- the present invention can also contain DNA encoding HGF as its active ingredient.
- Examples of the DNA encoding HGF include DNA having the nucleotide sequence represented by SEQ ID NO: 3 or 4, or DNA having a nucleotide sequence complementary to the DNA having the nucleotide sequence represented by SEQ ID NO: 3 or 4, and stringent DNA that hybridizes under various conditions, such as DNA encoding a protein having substantially the same quality as HGF, such as mitogenic activity, motogenic activity, and the like.
- the DNA that hybridizes with the DNA having the base sequence represented by SEQ ID NO: 3 or 4 is, for example, the above-mentioned DNA as a probe, the “mouth-to-one” hybridization method, and the plaque “hybridization method”. It means DNA obtained by using the method or Southern blot hybridization method.
- the DNA that hybridizes with the DNA having the base sequence represented by SEQ ID NO: 3 or 4 above is about 80% or more, preferably about 80% or more of the base sequence represented by SEQ ID NO: 3 or 4.
- Examples thereof include DNA having a base sequence having a homology of 90% or more, more preferably about 95% or more.
- Hybridization can be performed by a known method such as molecular cloning, A laboratory Manual, Third Edition (J. Sambrook et al., Cold Spring Harbor Lab. Press, 2001: hereinafter, molecular cloning. -Abbreviated as 3rd edition.) In addition, when using a commercially available library, it can be performed according to the method described in the attached instruction manual.
- the DNA encoding the HGF of the present invention is not limited to the above, and as long as the expressed protein is a DNA having substantially the same action as HGF, it is used as the DNA encoding the HGF of the present invention. it can.
- DNA encoding a partial peptide of HGF is included in the category of DNA encoding HGF of the present invention as long as it encodes a partial peptide having an action as HGF.
- the DNA encoding the HGF partial peptide may be any DNA as long as it has a base sequence encoding the above partial peptide.
- any of genomic DNA, genomic DNA library, cDNA derived from the above-mentioned cell 'tissue, cDNA library derived from the above-mentioned cell' tissue, and synthetic DNA may be used.
- the vector used for the library may be any of bacteriophage, plasmid, cosmid, phagemid and the like. In addition, it can also be directly amplified by RT-PCR using an mRNA fraction prepared from the cell 'tissue described above.
- DNA encoding the partial peptide of the present invention include (a) DNA having a partial base sequence of DNA having the base sequence represented by SEQ ID NO: 3 or 4, and (b) SEQ ID NO: 3 or 4 A DNA having a base sequence represented by a DNA having a base sequence that is complementary to a DNA having a partial base sequence and DNA that is hybridized under stringent conditions and has substantially the same activity as HGF. Examples thereof include DNA encoding a protein having DNA, or DNA having the partial base sequence of (a) or (b) above.
- the DNA can be easily obtained by, for example, a usual hybridization method or PCR method, and the DNA is specifically obtained with reference to the basic document such as the Molecular Cloning. it can.
- RNA encoding HGF or the partial peptide used in the present invention can also be used in the present invention as long as it can express HGF or the partial peptide by a reverse transcription enzyme.
- the RNA can also be obtained by known means.
- transplanted organ fibrosis inhibitor or immune tolerance-acquiring agent of the present invention can be applied to mammals (eg, rabbits, horses, pigs, hidges, nu, cats, etc.) in addition to humans.
- mammals eg, rabbits, horses, pigs, hidges, nu, cats, etc.
- transplanted organs to which the transplanted organ fibrosis inhibitor is applied examples include heart, kidney, liver, small intestine, spleen, skin, and cornea.
- the heart is particularly preferable.
- the immunological tolerance acquiring agent of the present invention can be applied to transplantation of hematopoietic cells and the like in addition to the transplanted organ.
- the transplanted organ fibrosis inhibitor or immune tolerance-acquiring agent of the present invention is capable of taking various preparation forms, for example, liquids, solids, capsules, etc. Generally, only HGF or a conventional carrier
- an injection, an inhalant, a suppository, or an oral preparation is used.
- the injection may be either an aqueous injection or an oily injection.
- an aqueous injection according to a known method, for example, an aqueous solvent (water for injection, purified water, etc.) is added to a pharmaceutically acceptable additive, for example, an isotonic agent (salt sodium, salt water).
- solubilizers such as alcohol (ethanol etc.), polyalcohol (propylene glycol, polyethylene glycol etc.) or nonionic surfactants (polysorbate 80, polyoxyethylene hydrogenated castor oil 50 etc.) can be used. Good.
- oil-based solvent for example, sesame oil or soybean oil may be used, and benzyl benzoate or benzyl alcohol may be used as a solubilizing agent.
- the prepared injection solution is usually filled in an appropriate ampoule or vial.
- liquid preparations such as injections are preferably stored after removing water by freezing or lyophilization.
- the freeze-dried preparation is used by re-dissolving it with distilled water for injection at the time of use.
- oral preparations include dosage forms such as tablets, granules, fine granules, powders, capsules, solutions, emulsions, suspensions or syrups. These preparations are produced by known methods.
- pharmaceutically acceptable additives such as excipients (lactose, sucrose, glucose, starch, crystalline cellulose, etc.), lubricants (magnesium stearate, talc, stearic acid, Calcium stearate, etc.), disintegrating agents (dampening, carmellose sodium, calcium carbonate, etc.) or binders (starch glue solution, hydroxypropylcellulose solution, carmellose solution, gum arabic solution, gelatin solution, sodium alginate solution, etc.) It can be manufactured by using.
- suitable coating agents for granules or tablets, suitable coating agents (gelatin, sucrose, gum arabic, carnaparou etc.) or enteric coating agents (eg cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropyl cellulose phthalate, carboxymethyl ester) are used. It may be coated with chilled cellulose or the like.
- enteric coating agents eg cellulose acetate phthalate, methacrylic acid copolymer, hydroxypropyl cellulose phthalate, carboxymethyl ester
- It may be coated with chilled cellulose or the like.
- known excipients such as magnesium stearate, calcium stearate, talc or light anhydrous key acid to improve fluidity and lubricity, crystals for pressurized fluidity Cellulose, lactose, or the above disintegrant can be selected as appropriate.
- HGF is mixed evenly with the above excipients, or granulated or granulated or coated with an appropriate coating agent to fill it into capsules, with an appropriate capsule base (such as gelatin).
- an appropriate capsule base such as gelatin.
- Glycerin or sorbitol In addition, it may be encapsulated with a capsule base with increased plasticity.
- These capsules may contain colorants or preservatives (sulfur dioxide, methyl noroxybenzoate, ethyl oxyraxybenzoate, propyl paraoxybenzoate, butyl paraoxybenzoate, etc.) as desired. it can.
- Capsules may be enteric coating capsules, gastroresistant capsules or controlled release capsules in addition to normal capsules.
- an ordinary capsule is filled with HGF coated with an enteric coating agent or HGF added with the above-mentioned appropriate excipient.
- capsules coated with an enteric coating agent, or capsules molded using an enteric polymer as a base can be filled with HGF or HGF supplemented with the above-mentioned appropriate excipients.
- a stabilizer sodium edetate, etc.
- a suspending agent such as sodium arabic, carmellose, etc.
- a corrigent simple syrup, glucose, etc.
- a fragrance is appropriately selected.
- suppositories can also be prepared by conventional methods on pharmaceutical preparations using conventional bases (for example, cacao butter, laurin butter, glyce gelatin, macrogol, witepsol, etc.).
- bases for example, cacao butter, laurin butter, glyce gelatin, macrogol, witepsol, etc.
- Inhalants can also be adjusted by conventional means in the preparation.
- the additive may be any additive generally used in inhalable preparations.
- the above-mentioned excipients, binding Agents, lubricants, preservatives, stabilizers, tonicity agents, pH adjusting agents or flavoring agents are used.
- a propellant a liquefied gas propellant or a compressed gas is used.
- liquefied gas propellant examples include fluorinated hydrocarbons (alternative fluorocarbons such as HCFC22, HCFC-123, HCFC-134a, and HCFC142), liquefied petroleum, dimethyl ether, and the like.
- fluorinated hydrocarbons alternative fluorocarbons such as HCFC22, HCFC-123, HCFC-134a, and HCFC142
- compressed gas examples include soluble gases (carbon dioxide, nitrous acid, nitrogen gas, etc.) or insoluble gases (nitrogen gas, etc.).
- the HGF used in the present invention can be made into a sustained-release preparation together with the biodegradable polymer.
- HGF can be expected to have effects such as maintaining blood concentration, reducing the number of doses, and reducing side effects, especially by making it a sustained-release preparation.
- the sustained-release preparation is produced according to a known method described in, for example, Drug Delivery System, Chapter 3 (CMC, 1986). Can.
- the biodegradable polymer used in the sustained-release preparation can be appropriately selected from the strengths of known biodegradable polymers. For example, polysaccharides such as starch, dextran or chitosan, collagen, gelatin, etc.
- Protein polyglutamic acid, polylysine, polyleucine, polyalanine or polymethionine, etc., polyamino acid, polylactic acid, polyglycolic acid, lactic acid'glycolic acid polymer or copolymer, poly force prolatatone, poly j8-hydroxybutyric acid, polyapple Polyesters such as acid, polyanhydride or fumaric acid 'polyethylene glycol' butyl pyrrolidone copolymer, polyalkyl cyanoacrylic acid such as polyorthoester or polymethyl-aminoacrylic acid, polycarbonate such as polyethylene carbonate or polypropylene carbonate, etc. It is.
- Polyester is preferable, and polylactic acid or lactic acid'glycolic acid polymer or copolymer is more preferable.
- the composition ratio (lactic acid Z glycolic acid) (mol%) varies depending on the sustained release period, for example, the sustained release period is about 2 weeks to 3 months, It is preferably about 100ZO to 50Z50 for about 2 weeks to 1 month.
- the weight average molecular weight of the polylactic acid-glycolic acid polymer or copolymer is generally about 5,000 to 20,000.
- the polylactic acid-glycolic acid copolymer can be produced according to a known production method, for example, the production method described in JP-A-61-28521.
- the blending ratio of the biodegradable polymer and HGF is not particularly limited. For example, ⁇ GF is about 0.01 to 30 wZw% with respect to the biodegradable polymer.
- the HGF content in each of the above-mentioned preparations can be appropriately adjusted according to the dosage form, applicable disease, degree of disease, age, or the like.
- HGF-encoding DNA can be achieved by conventional methods, for example, separate experimental medicine, basic gene therapy technology, Yodosha, 1996, separate experimental medicine, gene transfer & expression analysis experimental methods. , Yodosha, 1997, Gene Therapy Research Handbook edited by the Japanese Society of Gene Therapy, ENTS, 1999, and the like.
- various known preparation forms suitable for each of the above administration forms can be used.
- a microcapsule for example, host cells into which an expression plasmid containing DNA encoding HGF or DNA encoding HGF is introduced as a core substance, this is used as a known method (for example, coacervation method, interfacial weight).
- Legal or double The fine particles having a diameter of about 1 to 500, and preferably about 100 to 400 m can be produced by covering with a coating material according to the method such as the sulphur method.
- the coating material examples include carboxymethyl cellulose, sennellose acetate phthalate, ethyl cellulose, anoleic acid or its salt, gelatin, gelatin 'gum arabic, nitrocellulose, polybulal alcohol or hydroxypropyl cellulose, polylactic acid, polyglycol.
- High film-forming properties such as acid, chitosan alginate, cellulose sulfate monopoly (dimethyldiallyl) monoammonium chloride, hydroxyethyl methacrylate methyl methacrylate, chitosan carboxymethyl cellulose, alginate-polylysine-alginate Molecule.
- the DNA content in the preparation can be appropriately adjusted depending on the disease to be treated, the age, weight, etc. of the patient, but the daily dose is usually about 0.0001-10 mg as the DNA of the present invention, preferably Is about 0.001-10 mg.
- DNA encoding HGF and HGF can be used independently, or both can be used in combination.
- the immunosuppressive agent includes all of the immunosuppressive agents used for organ transplantation.
- the immunosuppressive agent include cyclosporin-tacrolimus (FK 506); IL-2 antibody, which is a calciurin inhibitor.
- FK 506 cyclosporin-tacrolimus
- IL-2 antibody which is a calciurin inhibitor.
- a certain zenapax, simlect TOR (target of rapamycin: a factor that constitutes a signal transduction pathway that regulates physiological functions related to cell growth according to nutritional state) inhibitors, etc .
- TOR target of rapamycin: a factor that constitutes a signal transduction pathway that regulates physiological functions related to cell growth according to nutritional state
- an antimetabolite For example, sellcept.
- the transplanted organ fibrosis inhibitor of the present invention is particularly useful for the prevention, improvement or treatment of transplanted organ fibrosis caused by long-term administration of tacrolimus.
- the transplanted organ fibrosis inhibitor or immune tolerance-acquiring agent of the present invention may appropriately contain other pharmaceutically active ingredients as long as they are not contrary to the purpose of the present invention.
- Such pharmaceutically active ingredients include, for example, coronary vasodilators (amyl nitrite, isosorbide nitrate, -to-glycerin, trapidil, etc.),
- 8 blockers oxprenolol, carteolol, bucmolol, bufetrol, propranolol) , Pindolol, etc.
- calcium antagonists diiltiazem, verapamil, diphdidipine, dicardipine, etc.
- peripheral circulatory disorders alprostadil alpha detas, caridinogenase, tocopherol, nicomol, etc.
- antiarrhythmic drugs azimarin) , Pro-powered inamide, lidocaine, etc.
- antihypertensive drugs
- the transplanted organ fibrosis-suppressing agent of the present invention can be administered by an appropriate administration route according to the preparation form.
- it can be administered in the form of an injection into veins, arteries, subcutaneous or intramuscular.
- the dosage is appropriately adjusted according to the patient's symptoms, age or weight, etc.
- HGF it is about 0.001 to 1000 mg, preferably about 0.01 to 100 mg per adult. It is appropriate to administer several divided doses.
- the transplanted organ fibrosis inhibitor of the present invention may be administered after organ transplantation, at the same time as administration of the immunosuppressive agent, before administration of the immunosuppressive agent, or immediately after administration.
- the transplanted organ fibrosis inhibitor of the present invention may begin to administer pre-organ transplant force.
- the immunological tolerance acquiring agent of the present invention is administered to a recipient patient at the same time as organ transplantation or before organ transplantation, and ⁇ is administered to a recipient patient after organ transplantation. It should be administered for at least about 2 weeks after transplantation.
- donor tissue different from the organ to be transplanted for example, when the transplanted organ is the heart, transplant the donor animal, such as lymphocytes, to the heart transplant recipient, together with the immunosuppressant.
- the tolerogenic agent of the present invention may be administered for at least about 2 weeks.
- the latter method allows recipients to be transplanted with donor organs that have acquired tolerance to the recipient. The rejection of transplanted organs can be suppressed.
- the administration route, dosage and administration method of the immunological tolerance acquiring agent of the present invention are the same as the administration route, dosage and administration method of the transplanted organ fibrosis inhibitor of the present invention described above.
- the “tissue” in this tissue refers to an organization involved in immunity, for example, bones, thymus, spleen, lymph nodes, tonsils, blood vessels, skin, intestine and other organs and tissues, or white blood cells, macrophages, lymphocytes (NKZ natural killer cells, TZ helper cells, TZ killer cells, B cells), immune cells such as rod-shaped cells, cyto force-in, or antibodies (immunoglobulin (Ig) G, IgA, IgM, IgD, IgE, etc.), Granulocytes (neutrophils, eosinophils, basophils) and the like.
- HGF 5-amino acid deletion HGF (HGF represented by SEQ ID NO: 2) was used as HGF.
- BALBZc mice and C3HZHe mice Two male mice (BALBZc mice and C3HZHe mice), 8 weeks old, weighing approximately 20 g, were used.
- BALBZc mice were used as donors and anesthetized with a combination of ketamine (100 gZkg) and xylazine (10 g Zkg). Under the anesthesia, the heart of a BALBZc mouse was perfused to 7.5% by mass with lmL of physiological saline containing palin, and then the heart was removed to obtain a heart for transplantation.
- C3H / He mice were anesthetized with a combination of ketamine (100 ⁇ g / kg) and xylazine (10 ⁇ g / kg), then opened, and the heart for transplantation, in which the BALBZc mouse force was also removed, was placed in the abdominal aorta and lower abdomen of C3HZHe mice. Ectopic transplantation was performed under the microscope into the vena cava.
- Prograf injection solution 5 mg (containing tacrolimus 5 mg ZmL; manufactured by Fujisawa Pharmaceutical Co., Ltd.) was used.
- tacrolimus was administered once a day for 27 gauge. It was administered subcutaneously for 60 days using a shooting needle.
- animals in the HGF-administered group were treated with a solution (0.2 mL; HGF250 gZkg) of HGF lmg added with saline 20 mL every 12 hours (500 gZkgZ day) for 14 days, and for control animals.
- Saline (0.2 mL) was similarly administered subcutaneously for 14 days using a 27 gauge needle every day.
- the day of transplantation surgery was defined as day 0, and the transplanted heart was excised on the 14th day, and formalin-fixed and paraffin-embedded according to a standard method to prepare heart tissue sections. Tissue sections were stained with matsuson trichrome. The stained tissue image is taken into a computer with a microscope CCD camera (OLYMPUS), and the NIH image analysis software (free software) is used. The ratio of was calculated.
- the fibrosis rate of the transplanted heart in the control animals was 22.3 ⁇ 7.7%, whereas in the HGF group, the fibrosis rate was suppressed to 15.6 ⁇ 1.3% (Fig. See 1;)).
- BALBZc mice were used as donors, and the heart for transplantation of BALBZc mice was transplanted into the abdominal aorta and inferior vena cava of C3HZHe mice.
- a solution 0.2 ⁇ ; ⁇ 250 ⁇ g / kg
- 20 mL of physiological saline in HGFlmg was dissolved every 12 hours (500 / z gZkgZ day) for 14 days, using a 27-gauge needle every day.
- Administered Sixty days after transplantation, the dorsal skin of surviving heart transplanted mice was excised, and skin lcm 2 collected from BALB / c mice or C57BLZ10 mice was transplanted.
- C3HZHe mice that survived 60 days after heart transplantation were transplanted with the skin of the heart donor BALBZc mouse.
- C3HZHe mice transplanted with skin the black hair of C3HZHe mice and the white hair skin of BALBZc mice, although no immunosuppressant was administered.
- transplanted organ fibrosis inhibitor and immune tolerance acquiring agent of the present invention are useful in the fields of organ transplantation and regenerative medicine.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006553821A JPWO2006077675A1 (ja) | 2005-01-24 | 2005-09-09 | 移植臓器の線維化抑制剤 |
US11/795,314 US7696170B2 (en) | 2005-01-24 | 2005-09-09 | Fibrosis inhibitor for implanted organ |
CA2594629A CA2594629C (en) | 2005-01-24 | 2005-09-09 | Fibrosis inhibitor for implanted organ |
EP05781995A EP1852124A4 (en) | 2005-01-24 | 2005-09-09 | FIBROSIS HEMMER FOR AN IMPLANTED ORGAN |
US12/695,532 US8076289B2 (en) | 2005-01-24 | 2010-01-28 | Fibrosis inhibitor for implanted organ |
US13/288,392 US8383588B2 (en) | 2005-01-24 | 2011-11-03 | Fibrosis inhibitor for implanted organ |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-016191 | 2005-01-24 | ||
JP2005016191 | 2005-01-24 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/795,314 A-371-Of-International US7696170B2 (en) | 2005-01-24 | 2005-09-09 | Fibrosis inhibitor for implanted organ |
US12/695,532 Division US8076289B2 (en) | 2005-01-24 | 2010-01-28 | Fibrosis inhibitor for implanted organ |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006077675A1 true WO2006077675A1 (ja) | 2006-07-27 |
Family
ID=36692070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/016653 WO2006077675A1 (ja) | 2005-01-24 | 2005-09-09 | 移植臓器の線維化抑制剤 |
Country Status (6)
Country | Link |
---|---|
US (3) | US7696170B2 (ja) |
EP (1) | EP1852124A4 (ja) |
JP (2) | JPWO2006077675A1 (ja) |
CN (1) | CN101102788A (ja) |
CA (1) | CA2594629C (ja) |
WO (1) | WO2006077675A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008105507A1 (ja) * | 2007-02-28 | 2008-09-04 | Keio University | 脊髄損傷治療薬剤 |
JP5419045B2 (ja) * | 2007-02-28 | 2014-02-19 | 学校法人慶應義塾 | 脊髄損傷治療薬剤 |
WO2016170704A1 (ja) * | 2015-04-23 | 2016-10-27 | 株式会社日本ハイポックス | 慢性呼吸器疾患治療剤及び心臓の線維化抑制組成物 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5051725B2 (ja) * | 2006-04-20 | 2012-10-17 | 国立大学法人大阪大学 | ポリグルタミン病の治療剤又は発病抑制剤 |
TWI486449B (zh) * | 2012-09-10 | 2015-06-01 | Nat Health Research Institutes | 製備免疫調節細胞之方法、依該方法所製備之細胞及其應用 |
US8927278B2 (en) * | 2012-09-10 | 2015-01-06 | National Health Research Institutes | Method for generating immunomodulatory cells, the cells prepared therefrom, and use thereof |
KR102271744B1 (ko) * | 2018-07-25 | 2021-07-01 | 가톨릭대학교 산학협력단 | 생체 모사형 인공방광 및 이의 제어방법 |
CN109771638A (zh) * | 2018-12-28 | 2019-05-21 | 中国人民解放军陆军军医大学第一附属医院 | 一种免疫耐受剂 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258111A (ja) * | 1994-03-18 | 1995-10-09 | Toshiichi Nakamura | 免疫抑制剤による副作用の軽減剤 |
JPH07300426A (ja) * | 1994-04-28 | 1995-11-14 | Toshiichi Nakamura | コラーゲン分解促進剤 |
JPH10194986A (ja) * | 1996-06-10 | 1998-07-28 | Snow Brand Milk Prod Co Ltd | 移植肝機能改善・再生促進剤 |
JP2000239182A (ja) * | 1999-02-19 | 2000-09-05 | Mitsubishi Chemicals Corp | 抗炎症剤 |
WO2001026694A1 (fr) * | 1999-10-08 | 2001-04-19 | Medgene Bioscience, Inc. | Therapie genique pour cardiomyopathie |
WO2002005840A1 (fr) * | 2000-07-18 | 2002-01-24 | Cardio, Inc. | Compositions medicinales favorisant la fixation de cellules transplantees |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566098B1 (en) * | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
JP3680114B2 (ja) * | 1993-09-17 | 2005-08-10 | 敏一 中村 | 脳神経障害治療剤 |
DK0922102T3 (da) * | 1996-07-03 | 2010-08-16 | Genentech Inc | Receptor-agonister af hepatocyt-vækstfaktor og anvendelser deraf |
ES2289795T3 (es) | 1997-12-03 | 2008-02-01 | Nakamura, Toshikazu | Preparacion para administracion intravenosa continua. |
JP2003246751A (ja) * | 2002-02-22 | 2003-09-02 | Sumitomo Pharmaceut Co Ltd | 骨髄移植後合併症治療剤 |
GB2414395B (en) | 2003-03-26 | 2007-10-31 | Kringle Pharma Inc | Asthma preparation |
-
2005
- 2005-09-09 CN CNA200580046955XA patent/CN101102788A/zh active Pending
- 2005-09-09 JP JP2006553821A patent/JPWO2006077675A1/ja active Pending
- 2005-09-09 US US11/795,314 patent/US7696170B2/en not_active Expired - Fee Related
- 2005-09-09 EP EP05781995A patent/EP1852124A4/en not_active Withdrawn
- 2005-09-09 CA CA2594629A patent/CA2594629C/en not_active Expired - Fee Related
- 2005-09-09 WO PCT/JP2005/016653 patent/WO2006077675A1/ja active Application Filing
-
2010
- 2010-01-28 US US12/695,532 patent/US8076289B2/en not_active Expired - Fee Related
-
2011
- 2011-04-08 JP JP2011086165A patent/JP2011173900A/ja active Pending
- 2011-11-03 US US13/288,392 patent/US8383588B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07258111A (ja) * | 1994-03-18 | 1995-10-09 | Toshiichi Nakamura | 免疫抑制剤による副作用の軽減剤 |
JPH07300426A (ja) * | 1994-04-28 | 1995-11-14 | Toshiichi Nakamura | コラーゲン分解促進剤 |
JPH10194986A (ja) * | 1996-06-10 | 1998-07-28 | Snow Brand Milk Prod Co Ltd | 移植肝機能改善・再生促進剤 |
JP2000239182A (ja) * | 1999-02-19 | 2000-09-05 | Mitsubishi Chemicals Corp | 抗炎症剤 |
WO2001026694A1 (fr) * | 1999-10-08 | 2001-04-19 | Medgene Bioscience, Inc. | Therapie genique pour cardiomyopathie |
WO2002005840A1 (fr) * | 2000-07-18 | 2002-01-24 | Cardio, Inc. | Compositions medicinales favorisant la fixation de cellules transplantees |
Non-Patent Citations (2)
Title |
---|
DATABASE CAPLUS [online] TASHIRO H ET AL: "Hepatocyte growth factor prevents chronic allograft dysfunction in liver-transplanted rats.", XP002993771, Database accession no. (2003:746114) * |
TASHIRO H. ET AL, TRANSPLANTATION., vol. 76, no. 5, 15 September 2003 (2003-09-15), pages 761 - 765, XP002994011 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008105507A1 (ja) * | 2007-02-28 | 2008-09-04 | Keio University | 脊髄損傷治療薬剤 |
CN101610783A (zh) * | 2007-02-28 | 2009-12-23 | 学校法人庆应义墪 | 脊髓损伤治疗剂 |
JP5419045B2 (ja) * | 2007-02-28 | 2014-02-19 | 学校法人慶應義塾 | 脊髄損傷治療薬剤 |
CN105311620A (zh) * | 2007-02-28 | 2016-02-10 | 学校法人庆应义塾 | 脊髓损伤治疗剂 |
CN101610783B (zh) * | 2007-02-28 | 2016-11-16 | 学校法人庆应义塾 | 脊髓损伤治疗剂 |
WO2016170704A1 (ja) * | 2015-04-23 | 2016-10-27 | 株式会社日本ハイポックス | 慢性呼吸器疾患治療剤及び心臓の線維化抑制組成物 |
Also Published As
Publication number | Publication date |
---|---|
CA2594629C (en) | 2014-12-16 |
CN101102788A (zh) | 2008-01-09 |
JPWO2006077675A1 (ja) | 2008-06-19 |
US20120149642A1 (en) | 2012-06-14 |
EP1852124A4 (en) | 2009-08-12 |
CA2594629A1 (en) | 2006-07-27 |
JP2011173900A (ja) | 2011-09-08 |
US20080274960A1 (en) | 2008-11-06 |
EP1852124A1 (en) | 2007-11-07 |
US20100137217A1 (en) | 2010-06-03 |
US8076289B2 (en) | 2011-12-13 |
US8383588B2 (en) | 2013-02-26 |
US7696170B2 (en) | 2010-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8383588B2 (en) | Fibrosis inhibitor for implanted organ | |
US20040259780A1 (en) | Method for treating diabetes and obesity | |
US11414474B2 (en) | Long-acting adrenomedullin derivatives | |
US8501680B2 (en) | Antagonists against interaction of PF4 and RANTES | |
EP1452182B1 (en) | Angiogenesis drugs | |
KR19990066965A (ko) | 신규 펩티드 | |
JP2007238487A (ja) | 脊髄損傷に対する嗅粘膜移植にhgfを用いた神経機能再建法 | |
CA2557884C (en) | An agent for promoting induction of vascular differentiation, comprising hepatocyte growth factor | |
JP5637854B2 (ja) | 腱骨移行部組織または靭帯骨移行部組織の再生促進剤 | |
US20030139361A1 (en) | Drug for gene therapy | |
CA2559958C (en) | A differentiation- or regeneration-inducing agent for alveoli | |
EP2351574B1 (en) | Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue | |
WO2000056350A9 (en) | Methods of use of beta 1-integrin inhibitors | |
JP4029221B2 (ja) | 心筋梗塞予防治療剤 | |
JPWO2002072131A1 (ja) | 肝疾患治療薬 | |
WO2002005840A1 (fr) | Compositions medicinales favorisant la fixation de cellules transplantees |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2594629 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006553821 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580046955.X Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005781995 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2966/KOLNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11795314 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005781995 Country of ref document: EP |